INTRODUCTION: Silibinin (SIL) has anti-inflammatory and antioxidant activity. Studies on its antimicrobial activity are not yet enlightening enough to consolidate the compound as an antimicrobial potential. This work aimed to evaluate the antibacterial activity of SIL against reference bacterial strains and clinical isolates. METHODS: Antibacterial activity was performed by determining the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) against standard strains of Gram-positive bacteria, including Enterococcus faecalis ATCC 29212 and Staphylococcus aureus ATCC 25923, as well as against Gram -negative Klebsiella pneumoniae ATCC 700603, Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922. Clinical isolates of resistant bacteria were also analyzed. Next, the interaction of the compound with the antibiotic ciprofloxacin (CIP) was analyzed using the Checkerboard technique. RESULTS: MIC values ranged from 64-1,024 µg/mL for standard strains and MBC from 128-1,024 µg/mL. For clinical isolates, MIC ranged from 128-1,024 µg/mL and MBC was equivalent to or greater than 1,024 µg/mL. In the study of the interaction of SIL with CIP, synergistic activity was observed against S. aureus ATCC 25923, additive against E. faecalis ATCC 29212 and indifferent against P. aeruginosa ATCC 27853. CONCLUSION: The SIL compound presents bactericidal and bacteriostatic action against different strains of standard and/or resistant bacteria, as well as significant CIP interaction against S. aureus strains. Thus, preliminary data suggest the possibility of the isolated and/or combined use of SIL for the treatment of infections caused by pathogens of clinical interest.